Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
View:
• Adult participants 19 years of age or older
• Participants who will receive ozanimod according to the approved label after enrollment
• Participants who sign the informed consent form voluntarily
Locations
Other Locations
Republic of Korea
Bristol-Myers Squibb YH
RECRUITING
Seoul
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2024-04-19
Estimated Completion Date: 2028-04-01
Participants
Target number of participants: 3000
Treatments
Participants with moderate to severe active ulcerative colitis treated with ozanimod
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb